John R. Stuelpnagel Sells 5,000 Shares of 10x Genomics, Inc. (NASDAQ:TXG) Stock

10x Genomics, Inc. (NASDAQ:TXG) Director John R. Stuelpnagel sold 5,000 shares of 10x Genomics stock in a transaction on Friday, July 16th. The shares were sold at an average price of $170.31, for a total value of $851,550.00. Following the transaction, the director now owns 396,116 shares in the company, valued at approximately $67,462,515.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

John R. Stuelpnagel also recently made the following trade(s):

  • On Thursday, June 17th, John R. Stuelpnagel sold 5,000 shares of 10x Genomics stock. The shares were sold at an average price of $199.38, for a total value of $996,900.00.
  • On Monday, May 17th, John R. Stuelpnagel sold 7,500 shares of 10x Genomics stock. The shares were sold at an average price of $141.57, for a total value of $1,061,775.00.

Shares of NASDAQ TXG opened at $184.06 on Thursday. The company has a 50-day moving average price of $180.49. 10x Genomics, Inc. has a one year low of $92.54 and a one year high of $208.99. The stock has a market capitalization of $20.21 billion, a P/E ratio of -36.52 and a beta of 1.29.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Tuesday, May 4th. The company reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.16. 10x Genomics had a negative return on equity of 13.90% and a negative net margin of 160.22%. The firm had revenue of $105.82 million for the quarter, compared to the consensus estimate of $102.75 million. As a group, sell-side analysts forecast that 10x Genomics, Inc. will post -0.62 earnings per share for the current fiscal year.

Separately, Zacks Investment Research upgraded 10x Genomics from a “sell” rating to a “hold” rating in a report on Thursday, March 25th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $192.44.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. IFM Investors Pty Ltd boosted its stake in shares of 10x Genomics by 38.1% during the 2nd quarter. IFM Investors Pty Ltd now owns 9,384 shares of the company’s stock worth $1,838,000 after acquiring an additional 2,589 shares in the last quarter. Vigilant Capital Management LLC boosted its stake in shares of 10x Genomics by 7.7% during the 2nd quarter. Vigilant Capital Management LLC now owns 62,027 shares of the company’s stock worth $12,146,000 after acquiring an additional 4,437 shares in the last quarter. KB Financial Partners LLC bought a new stake in shares of 10x Genomics during the 1st quarter worth about $26,000. Principal Financial Group Inc. boosted its stake in shares of 10x Genomics by 6.0% during the 1st quarter. Principal Financial Group Inc. now owns 23,248 shares of the company’s stock worth $4,208,000 after acquiring an additional 1,320 shares in the last quarter. Finally, Slow Capital Inc. boosted its stake in shares of 10x Genomics by 37.0% during the 1st quarter. Slow Capital Inc. now owns 6,052 shares of the company’s stock worth $1,095,000 after acquiring an additional 1,636 shares in the last quarter. Hedge funds and other institutional investors own 68.72% of the company’s stock.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products.

Further Reading: What does an equal weight rating mean?

Insider Buying and Selling by Quarter for 10x Genomics (NASDAQ:TXG)

Receive News & Ratings for 10x Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 10x Genomics and related companies with MarketBeat.com's FREE daily email newsletter.